Clinical Trial Update: An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia [Phase 4]

View source ↗

Summary

An 8-week open-label Phase 4 study evaluating accelerated and slower switching to Xanomeline/Trospium in participants with schizophrenia who previously received…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• TROSPIUM CHLORIDE
• Xanomeline (Xanomeline)

Snippet

Sponsor: Collaborative Neuroscience Research, LLC | Conditions: Schizophrenia Disorders | Phase 4 | Status: NOT_YET_RECRUITING